收费全文 | 1252786篇 |
免费 | 95110篇 |
国内免费 | 1516篇 |
耳鼻咽喉 | 16266篇 |
儿科学 | 40817篇 |
妇产科学 | 34934篇 |
基础医学 | 187673篇 |
口腔科学 | 34675篇 |
临床医学 | 116639篇 |
内科学 | 244166篇 |
皮肤病学 | 27255篇 |
神经病学 | 100999篇 |
特种医学 | 46735篇 |
外国民族医学 | 265篇 |
外科学 | 177876篇 |
综合类 | 25677篇 |
一般理论 | 570篇 |
预防医学 | 103573篇 |
眼科学 | 27942篇 |
药学 | 92140篇 |
6篇 | |
中国医学 | 1950篇 |
肿瘤学 | 69254篇 |
2018年 | 13407篇 |
2017年 | 10327篇 |
2016年 | 11192篇 |
2015年 | 12936篇 |
2014年 | 17948篇 |
2013年 | 27440篇 |
2012年 | 37566篇 |
2011年 | 39945篇 |
2010年 | 22987篇 |
2009年 | 22196篇 |
2008年 | 37738篇 |
2007年 | 40365篇 |
2006年 | 39953篇 |
2005年 | 39065篇 |
2004年 | 37532篇 |
2003年 | 35882篇 |
2002年 | 34791篇 |
2001年 | 55924篇 |
2000年 | 56890篇 |
1999年 | 47750篇 |
1998年 | 12459篇 |
1997年 | 11309篇 |
1996年 | 11714篇 |
1995年 | 11831篇 |
1994年 | 11046篇 |
1993年 | 10323篇 |
1992年 | 38152篇 |
1991年 | 37678篇 |
1990年 | 36442篇 |
1989年 | 35260篇 |
1988年 | 32681篇 |
1987年 | 32028篇 |
1986年 | 30519篇 |
1985年 | 28793篇 |
1984年 | 21920篇 |
1983年 | 19150篇 |
1982年 | 11321篇 |
1981年 | 10277篇 |
1979年 | 20896篇 |
1978年 | 15364篇 |
1977年 | 12710篇 |
1976年 | 11763篇 |
1975年 | 12750篇 |
1974年 | 15522篇 |
1973年 | 15305篇 |
1972年 | 14480篇 |
1971年 | 13521篇 |
1970年 | 12753篇 |
1969年 | 12042篇 |
1968年 | 11209篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献